OAN Staff Katherine Mosack
2:41 PM – Wednesday, February 11, 2026
Moderna announced that the U.S. Food and Drug Administration (FDA) has refused to consider its application for a new flu vaccine using mRNA technology.
On Tuesday, the company reported in a news release that it had received a Refusal-to-File (RTF) letter from the FDA for its Investigational Seasonal Influenza Vaccine, mRNA-1010, despite filing a Priority Review Voucher to “facilitate a timely review of the application.”
The RTF letter, signed by Center Director Vinayak Prasad, MD, MPH, cited the company’s choice…




